The authors acknowledged that the study was undertaken to evaluate a targeted medication approach in a group with recent-onset schizophrenia. While it is now clear that targeted medication approaches should not be generally recommended for patients who have had multiple episodes of illness (2), this study should raise similar concerns about its use in first-episode patients in remission. The fact that only 13% of the patients needed to be rehospitalized in the first 2 years of no medication is hardly reassuring. It is not the risk or cost of hospitalization that argues for continuous treatment, nor is it the hypothetical risk of psychosis-induced neurotoxicity. It is the need to spare individuals with schizophrenia and their families from the terrible suffering and disruption to their lives that all too frequently accompany such recurrences. Hospitalization is too crude a measure of outcome. Assessments of outcome need to take into account the degree to which patients are able to function, as well as their quality of life and risk of suicide in the long term.